PsA asso w/ higher risk of preterm births in women Scandinavian registries 688 PsA pregnancies 8% preterm births vs. 4.5% general population OR 1.8 16.4% if bDMARD combination OR 4 3.1% if bDMARD monotherapy OR 0.7 bDMARDs combo probably a surrogate of high disease activity

Difficult-to-Manage AxSpA: Global Prevalence and Associated Factors The concept of D2M axSpA is a recent development, with the first expert consensus definition published by the Assessment of SpondyloArthritis International Society (ASAS) earlier this year. https://t.co/KmfJvAtwp0

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.

Live Daily Eular 2025 Recap Day 2 https://t.co/78NYTcFPG6

• Dr. John Cush

Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj

Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet 🔴Performance tests (SPPB) were associated with 🔴Global functioning and health (ASAS-HI and other PROs) What does this mean? Improving physical performance could enhance PROs & QOL #EULAR2025 POS# @RheumNow @XBaraliakos https://t.co/P3Q5NDvtoj

• https://x.com/Nellziade/status/1933073555199328480/photo/1

#D2M_axSpA_saga 🇬🇷 Prevalence of D2M axSpA in 395 patients: 10.1% Associated factors: 🔹️High disease activity at diagnosis 🔹️Comorbidities (high BMI, smoking, depression) 🔹️Unemployment Kougkas et al. POS#0121 #EULAR2025 @rheumnow https://t.co/vcPcTATTx5

• https://x.com/Nellziade/status/1933081226014757022/photo/1

What's the difference between PIPsA & NIPsA? (Persistent Inflammatory confirmed by IMAGING vs. Non inflammatory PsA) 🔹️Cross-sectional study 🔹️517 pts under b/tsDMARDs 🔹️10.3% D2T 🔹️57% PIPsA / 43% NIPsA 👇 Distinct phenotypes 👇 OP0176 #EULAR2025 @rheumnow https://t.co/YGHpbeE6ws

• https://x.com/Nellziade/status/1933265951266320720/photo/1

What happens to the prevalence of D2T PsA if we use different parameters in its definition? Data from 5 Nordic registries including 13,872 patients showed a variation from 37% (less stringent) to 0.6% (more stringent)! OP0177 #EULAR2025 @rheumnow https://t.co/QbF15t3Zrz

• https://x.com/Nellziade/status/1933270413477314604/photo/1

#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj

• https://x.com/Yuz6Yusof/status/1933537755377668361/photo/1

🚨Diagnostic delays are real in axSpA: -Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA. -Increases disease burden and productivity losses. -EMMs can present before articular sx -Uveitis and IBD associated with longer dx delays. -Diagnosis has improved since https://t.co/rWMwG7Ewwe

• https://x.com/AdelaCastro222/status/1933523663455740384/photo/1
• https://x.com/AdelaCastro222/status/1933523663455740384/photo/1

#guidelines everywhere @jeffsparks presents points of interest from #ACR #ILD #recommendations - a joint venture with American College of Chest Physicians While simultaneously the EULAR ILD recommendations are being unveiled! @RheumNow #EULAR2025 @eular_org @ACRheum https://t.co/cfHrqIAbx9

• https://x.com/Janetbirdope/status/1933523685849079905/photo/1
• https://x.com/Janetbirdope/status/1933523685849079905/photo/1

A machine learning (ML) model using electronic medical record (EMR) data from 396,000 Mayo Clinic primary care patients identified undiagnosed psoriatic arthritis (PsA) with area under the curve (AUC) 79.6%. Key predictors: psoriasis, joint pain, tenosynovitis, https://t.co/VsYevnJEjK

• https://x.com/synovialjoints/status/1933526164821188912/photo/1

In 1314 PsA patients, cumulative methotrexate dose was not associated with liver fibrosis (OR 0.99). Instead, higher BMI (OR 1.03) & diabetes (OR 5.03) were key drivers. MASLD, not MTX, may underlie fibrosis risk in PsA. APRI >0.7 used for fibrosis detection. Abstract#POS0111 https://t.co/zsX7NUOT9m

• https://x.com/synovialjoints/status/1933527987514646938/photo/1

#EULAR2025 Abstr#OP0273 Single arm, Open Label Phase 2 trial showed Certolizumab (given in WKS 8-28) +LMWH+LDA in Antiphospholipid syndrome reported 20% Adverse Pregnancy Outcomes in ITT; 18% Per Protocol. Met prespecified criterion (20%); expected LMWH+LDA (40%) @RheumNow https://t.co/ynQ2h2NTQ7

• https://x.com/Yuz6Yusof/status/1933532364443168839/photo/1